Growth Factor News and Research

RSS

Tumor Recurrence Prediction from Multi-Omics Information by Deep Learning

MULGONET combines deep learning and multi-omics analysis to predict tumor recurrence, addressing interpretability and enhancing cancer prognosis understanding.

16 Apr 2025

Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth

In an extraordinary achievement of advanced multiplexed genome engineering, Colossal Biosciences announces the birth of the Colossal Woolly Mouse—mice engineered to express multiple key mammoth-like traits that provide adaptations to life in cold climates.

5 Mar 2025

Breakthrough Fluorescent Dye Sets New Standard for Long-Term Cellular Imaging

A research team at POSTECH (Pohang University of Science and Technology) has successfully developed a super-photostable organic dye after two years of dedicated research-demonstrating perseverance akin to that of Marie Curie, who painstakingly extracted just 0.1 grams of radium from eight tons of ore to earn her Nobel Prize.

28 Feb 2025

Natural Cytotoxic Agents Enhance Cancer Cell Susceptibility to Ferroptosis

One particular challenge in the treatment of cancer is therapy resistance. An international research team has now discovered a mechanism that opens up new treatment strategies for tumors in which conventional chemotherapeutic agents have reached their limits.

26 Feb 2025

New Lipid Nanoparticles Deliver mRNA for Lung Tissue Regeneration

New research from the Perelman School of Medicine at the University of Pennsylvania suggests that a combination of messenger RNA (mRNA) and a novel lipid nanoparticle (LNP) could potentially be used to repair lung damage.

24 Feb 2025

Study Uncovers Immune Cell Interaction Driving Aggressive Brain Tumor Growth

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.

11 Feb 2025

AI Model 'MUSK' Advances Cancer Diagnosis with Multimodal Data Integration

MUSK, a vision-language model, enhances cancer diagnosis by integrating multimodal data, outperforming existing methods in prognosis and treatment predictions.

23 Jan 2025

The Mechanics Behind Crocodile Morphology: A Breakthrough in Evolutionary Biology

How do humans account for the variety of morphologies found in living things? Genetics is usually the first explanation that comes to mind, but it is not the only one.

12 Dec 2024

Programmable G-protein-coupled receptors redefine therapeutic applications.

This study demonstrates the development of PAGERs (programmable antigen-gated engineered receptors), combining antigen specificity, modular adaptability, and drug-controlled activation, with potential applications in synthetic biology, therapeutics, and neuroscience.

12 Dec 2024

Caterpillar Fungus Compound Blocks Cancer Growth Signals Within 30 Minutes

Cordycepin, derived from fungi, shows promise in cancer therapy by inhibiting growth factor signaling pathways critical for cell proliferation and survival.

15 Nov 2024

CRISPR/Cas System Revolutionizes Tumor Variant and Biomarker Detection

The CRISPR-Cas system is transforming tumor biomarker detection, enabling ultra-sensitive diagnostics and improving accuracy in cancer detection and monitoring.

4 Sep 2024

European Commission Approves Erdafitinib for Advanced Urothelial Carcinoma

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA®▼(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment setting.

30 Aug 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Study Uncovers Biomarkers for Low Muscle Mass, Offering Insights for Personalized Prevention

Machine learning models to analyze computed tomography (CT) images of the chest and a proteomics approach to determine blood protein biomarkers.

15 Aug 2024

Mucus-Based Bioink Shows Promise for 3D-Printed Lung Tissue

Each year, lung illnesses claim the lives of millions of people worldwide. There are few available treatments, and animal models used to research these conditions and potential drugs are insufficient. Researchers have now successfully developed a mucus-based bioink for 3D printing lung tissue.

31 Jul 2024